Zacks Research Brokers Lower Earnings Estimates for BIO

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities research analysts at Zacks Research cut their Q2 2025 earnings estimates for shares of Bio-Rad Laboratories in a note issued to investors on Monday, June 9th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.03 per share for the quarter, down from their previous forecast of $2.14. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $2.60 EPS, FY2025 earnings at $9.37 EPS, Q1 2026 earnings at $2.80 EPS, Q2 2026 earnings at $2.45 EPS, Q3 2026 earnings at $2.64 EPS, Q4 2026 earnings at $2.94 EPS and FY2026 earnings at $10.83 EPS.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The firm had revenue of $585.40 million for the quarter, compared to analysts’ expectations of $573.01 million. During the same period last year, the firm earned $2.30 earnings per share. The business’s revenue for the quarter was down 4.2% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Company cut their price objective on Bio-Rad Laboratories from $260.00 to $245.00 and set an “equal weight” rating on the stock in a report on Monday. Citigroup cut their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. UBS Group reduced their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Royal Bank of Canada cut their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $324.25.

Bio-Rad Laboratories Trading Up 2.1%

NYSE:BIO opened at $230.36 on Wednesday. The business’s 50-day moving average price is $236.07 and its two-hundred day moving average price is $283.95. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $387.99. The firm has a market capitalization of $6.27 billion, a price-to-earnings ratio of -3.54 and a beta of 0.93. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several hedge funds have recently bought and sold shares of BIO. Metis Global Partners LLC lifted its stake in shares of Bio-Rad Laboratories by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock worth $234,000 after buying an additional 30 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Bio-Rad Laboratories by 13.2% during the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company’s stock worth $87,000 after buying an additional 31 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Bio-Rad Laboratories by 0.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company’s stock valued at $1,488,000 after acquiring an additional 32 shares during the period. CIBC Asset Management Inc grew its stake in shares of Bio-Rad Laboratories by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company’s stock valued at $234,000 after acquiring an additional 34 shares in the last quarter. Finally, Picton Mahoney Asset Management grew its stake in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 35 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.